

|   |   |                     |
|---|---|---------------------|
| Informazione<br>Regolamentata n.<br>0472-2-2023 | Data/Ora Ricezione<br>17 Gennaio 2023<br>15:03:09 | Euronext Star Milan |
|---|---|---------------------|

Societa' : BB BIOTECH  
Identificativo : 171556  
Informazione  
Regolamentata  
Nome utilizzatore : BIOTECHNSS01 - Alderuccio  
Tipologia : REGEM  
Data/Ora Ricezione : 17 Gennaio 2023 15:03:09  
Data/Ora Inizio : 17 Gennaio 2023 15:03:16  
Diffusione presunta  
Oggetto : 2023 Corporate events calendar

*Testo del comunicato*

Vedi allegato.

Press Release, January 17, 2023

## Corporate events calendar – 2023

|            |  |
|------------|--|
| 20/01/2023 | Portfolio as of December 31, 2022                                |
| 17/02/2023 | Annual Report 2022   |
| 23/03/2023 | Annual General Meeting<br>Park Casino - 8200 Schaffhausen - 3 pm |
| 21/04/2023 | Interim Report as of March 31, 2023                              |
| 21/07/2023 | Interim Report as of June 30, 2023                               |
| 20/10/2023 | Interim Report as of September 30, 2023                          |

The dates of the meetings with the financial community will be made public later on.

### For further information:

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland  
Tanja Chicherio, Tel. +41 44 267 67 07, [tch@bellevue.ch](mailto:tch@bellevue.ch)  
[www.bbbiotech.com](http://www.bbbiotech.com)

[www.bbbiotech.com](http://www.bbbiotech.com)

### Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with approx. CHF 3.5 billion in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

Fine Comunicato n.0472-2

Numero di Pagine: 3